Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic : A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial

OBJECTIVES: The aim of this study is to assess the efficacy of the use of pre-exposure prophylaxis (PrEP) with hydroxychloroquine against placebo in healthcare workers with high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in reducing their risk of coronavirus disease 2019 (COVID-19) disease during an epidemic period. As secondary objectives, we would like to: i) assess the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of exposure to SARS-CoV-2 (defined by seroconversion) during an epidemic period, ii) evaluate the safety of PrEP with hydroxychloroquine in adults, iii) describe the incidence of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 infection, iv) identify clinical, analytical and microbiological predictors of COVID-19 among healthcare workers at high risk of SARS-CoV-2 infection, v) set up a repository of serum samples obtained from healthcare workers at high risk of SARS-CoV-2 infection for future research on blood markers to predict SARS-CoV-2 infection

TRIAL DESIGN: Multicentre double-blind parallel design (ratio 1:1) randomized controlled clinical trial

PARTICIPANTS: Approximately 440 healthcare workers of four Spanish hospitals (Hospital Clínic of Barcelona, Hospital de la Santa Creu i Sant Pau of Barcelona, Hospital Plató of Barcelona, Hospital General de Granollers, Barcelona) will be recruited. Participants are considered to be at high-risk of SARS-CoV-2 infection due to their frequent contact with suspected and confirmed cases of COVID-19. For eligibility, healthcare workers with 18 years old or older working at least 3 days a week in a hospital with both negative SARS-CoV-2 polymerase chain reaction (PCR) assays and serological COVID-19 rapid diagnostic tests (RDT) are invited to participate. Participants with any of... Full description

Year of Publication: 2020
Contained in: Trials Vol. 21, No. 1 (2020), p. 688
All journal articles: Search for all articles in this journal
Language: English
Contributors: Grau-Pujol, Berta | Author
Camprubí, Daniel
Marti-Soler, Helena
Fernández-Pardos, Marc
Guinovart, Caterina
Muñoz, Jose
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: COVID-19
Letter
Randomised controlled trial
Spain
double-blinded
healthcare workers
hydroxychloroquine
pre-exposure
prophylaxis
protocol
ISSN: 1745-6215
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Revised 01.08.2020
published: Electronic
Citation Status In-Process
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32727613
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1186/s13063-020-04621-7
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 07554nma a2200757 c 4500
001 NLM313958084
003 DE-601
005 20200801213813.0
007 cr uuu---uuuuu
008 200730s2020 000 0 eng d
024 7 |a 10.1186/s13063-020-04621-7  |2 doi 
028 5 2 |a pubmed20n1287.xml 
035 |a (DE-599)NLM32727613 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Grau-Pujol, Berta 
245 1 0 |a Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic  |h Elektronische Ressource  |b A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial 
300 |a Online-Ressource 
500 |a Date Revised 01.08.2020 
500 |a published: Electronic 
500 |a Citation Status In-Process 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a OBJECTIVES: The aim of this study is to assess the efficacy of the use of pre-exposure prophylaxis (PrEP) with hydroxychloroquine against placebo in healthcare workers with high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in reducing their risk of coronavirus disease 2019 (COVID-19) disease during an epidemic period. As secondary objectives, we would like to: i) assess the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of exposure to SARS-CoV-2 (defined by seroconversion) during an epidemic period, ii) evaluate the safety of PrEP with hydroxychloroquine in adults, iii) describe the incidence of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 infection, iv) identify clinical, analytical and microbiological predictors of COVID-19 among healthcare workers at high risk of SARS-CoV-2 infection, v) set up a repository of serum samples obtained from healthcare workers at high risk of SARS-CoV-2 infection for future research on blood markers to predict SARS-CoV-2 infection 
520 |a TRIAL DESIGN: Multicentre double-blind parallel design (ratio 1:1) randomized controlled clinical trial 
520 |a PARTICIPANTS: Approximately 440 healthcare workers of four Spanish hospitals (Hospital Clínic of Barcelona, Hospital de la Santa Creu i Sant Pau of Barcelona, Hospital Plató of Barcelona, Hospital General de Granollers, Barcelona) will be recruited. Participants are considered to be at high-risk of SARS-CoV-2 infection due to their frequent contact with suspected and confirmed cases of COVID-19. For eligibility, healthcare workers with 18 years old or older working at least 3 days a week in a hospital with both negative SARS-CoV-2 polymerase chain reaction (PCR) assays and serological COVID-19 rapid diagnostic tests (RDT) are invited to participate. Participants with any of the following conditions are excluded: pregnancy, breastfeeding, ongoing antiviral, antiretroviral or corticosteroids treatment, chloroquine or hydroxychloroquine uptake the last month or any contraindication to hydroxychloroquine treatment 
520 |a INTERVENTION AND COMPARATOR: Eligible participants will be allocated to one of the two study groups: Intervention group (PrEP): participants will receive the standard of care and will take 400mg of hydroxychloroquine (2 tablets of 200 mg per Dolquine® tablet) daily the first four consecutive days, followed by 400 mg weekly for a period of 6 months 
520 |a CONTROL GROUP: participants will receive placebo tablets with identical physical appearance to hydroxychloroquine 200 mg (Dolquine®) tablets following the same treatment schedule of the intervention group. Both groups will be encouraged to use the personal protection equipment (PPE) for COVID-19 prevention according to current hospital guidelines 
520 |a MAIN OUTCOMES: The primary endpoint will be the number of confirmed cases of a COVID-19 (defined by a positive PCR for SARS-CoV-2 or symptoms compatible with COVID-19 with seroconversion) in the PrEP group compared to the placebo group at any time during the 6 months of the follow-up in healthcare workers with negative SARS-CoV-2 PCR and serology at day 0. As secondary endpoints, we will obtain: i) the SARS-CoV-2 seroconversion in the PrEP group compared to placebo during the 6 months of follow-up in healthcare workers with negative serology at day 0; ii) the occurrence of any adverse event related with hydroxychloroquine treatment; iii) the incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers in the non-PrEP group, among the total of healthcare workers included in the non-PrEP group during the study period; iv) the risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19; v) a repository of serum samples obtained from healthcare workers confirmed COVID-19 cases for future research on blood markers to predict SARS-CoV-2 infection 
520 |a RANDOMISATION: Participants meeting all eligibility requirements will be allocated to one of the two study arms (PrEP with hydroxychloroquine or non-PrEP control group) in a 1:1 ratio using simple randomisation with computer generated random numbers 
520 |a BLINDING (MASKING): Participants, doctors and nurses caring for participants, and investigators assessing the outcomes will be blinded to group assignment 
520 |a NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Each intervention group will have 220 participants, giving a total of 440 participants 
520 |a TRIAL STATUS: The current protocol version is 1.5, 2nd of June 2020. Two hundred and seventy-fiveparticipants were recruited and completed first month follow-up until date. The estimated sample size could not be reached yet due to the declining national epidemic curve. Thus, 275 is the total number of participants included until date. The study has been suspended (26th of June) until new epidemic curve occurs 
520 |a TRIAL REGISTRATION: This trial was registered on April 2nd 2020 at clinicaltrials.gov with the number NCT04331834 
520 |a FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol 
611 2 7 |a Letter  |2 gnd 
655 7 |a COVID-19  |2 gnd 
655 7 |a Randomised controlled trial  |2 gnd 
655 7 |a Spain  |2 gnd 
655 7 |a double-blinded  |2 gnd 
655 7 |a healthcare workers  |2 gnd 
655 7 |a hydroxychloroquine  |2 gnd 
655 7 |a pre-exposure  |2 gnd 
655 7 |a prophylaxis  |2 gnd 
655 7 |a protocol  |2 gnd 
689 0 0 |A f  |a Letter 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a Randomised controlled trial 
689 1 2 |a Spain 
689 1 3 |a double-blinded 
689 1 4 |a healthcare workers 
689 1 5 |a hydroxychloroquine 
689 1 6 |a pre-exposure 
689 1 7 |a prophylaxis 
689 1 8 |a protocol 
689 1 |5 DE-601 
700 1 |a Camprubí, Daniel 
700 1 |a Marti-Soler, Helena 
700 1 |a Fernández-Pardos, Marc 
700 1 |a Guinovart, Caterina 
700 1 |a Muñoz, Jose 
773 0 8 |i in  |t Trials  |g Vol. 21, No. 1 (2020), p. 688  |q 21:1<688  |w (DE-601)NLM161324320  |x 1745-6215 
856 4 1 |u http://dx.doi.org/10.1186/s13063-020-04621-7  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 21  |j 2020  |e 1  |b 29  |c 07  |h 688